Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 4 5 Next >
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN SOPH
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces New $200 Million Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Earns 2025 Great Place To Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Inducement Awards
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Senior Leadership Transition
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.